CRNX Pengajuan SEC - Crinetics Pharmaceuticals, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300Q1CNFXK5P31D28
CIK	1658247

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Crinetics Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 7, 2025	8-K	FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Co
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crine
August 7, 2025	EX-99.1	Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September Exhibit 99.1 Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the Global Development Program for Atumelnant Across Multiple Trials, Including the BALANCE-CAH
June 30, 2025	EX-99.1	Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline Long-term efficacy and safety data on PALSONIFYTM (paltusotine) in acromegaly to be presented, including evidence of bo Exhibit 99.1 Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline Long-term efficacy and safety data on PALSONIFYTM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmac
June 30, 2025	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Comm
June 26, 2025	EX-99.1	This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are fo Research & Development Day June 26, 2025 – New York Exhibit 99.1 This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements, including, but not limited to, statements regarding: the po
June 26, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Comm
June 12, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Comm
May 20, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crin
May 8, 2025	EX-99.1	Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUF Exhibit 99.1 Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal Hyperplasia to Initiate with Uncompromisi
May 8, 2025	EX-10.2	Employment Agreement, effective as of February 21, 2025, between Crinetics Pharmaceuticals, Inc. and Tobin Schilke Exhibit 10.2 *Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[......]”) in this exhibit.** Employment Agreement This Employment Agreement (the "Agreement") is made and entered into as of February 28, 2025, by and b
May 8, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Commi
April 23, 2025	DEF 14A	COMPENSATION DISCUSSION AND ANALYSIS Report of the Compensation Committee of the Board of Directors Summary Compensation Table 2024 Grants of Plan Based Awards Outstanding Equity Awards at Fiscal Year End Option Exercises and Stock Vested Potential P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
April 23, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
April 4, 2025	EX-10.1	Consulting Agreement, effective as of April 1, 2025, between Crinetics Pharmaceuticals, Inc. and Marc Wilson Exhibit 10.1 INDEPENDENT CONSULTANT AGREEMENT THIS INDEPENDENT CONSULTANT AGREEMENT (this “Agreement”) is made, as of the Effective Date (as defined herein), by and between Crinetics Pharmaceuticals, Inc. (the “Company”), and Marc J.S. Wilson (“Consultant”). A. Consultant was employed by the Company pursuant to that certain Amended and Restated Employment Agreement dated May 22, 2018 (the “Employm
April 4, 2025	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2025 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Com
February 27, 2025	S-8	As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.
February 27, 2025	EX-10.27	Employment Agreement Exhibit 10.27 Employment Agreement This Employment Agreement (the "Agreement") is made and entered into as of December 16, 2024, by and between Isabel Kalofonos, (the "Executive") and Crinetics Pharmaceuticals, Inc, a Delaware corporation (the "Company"). WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth herein; and WHEREAS, the Executive desires to be empl
February 27, 2025	EX-99.1	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder Engagement Efforts Expecting to Initiate Four Late-Stage Trials and Additional Early-Stage Trials from Development Pipeli
February 27, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc.
February 27, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
February 27, 2025	EX-10.19	Amendment No. 4 to the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan Exhibit 10.19 AMENDMENT TO THE CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN THIS AMENDMENT TO THE CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (this “Amendment”), effective as of December 13, 2024, is made and adopted by Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not other
February 27, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Crinetics Pharmaceuticals, Inc.
February 24, 2025	EX-99.1	Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer Exhibit 99.1 Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer SAN DIEGO –February 24, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Tobin “Toby” Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, h
February 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2025 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
February 10, 2025	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Crinetics Pharmaceuticals, Inc.
January 14, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (C
January 14, 2025	EX-99.1	Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that statements contained in this presentation regarding matters that are not January 2025 J.P. Morgan Healthcare Conference ® Exhibit 99.1 Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the comp
January 10, 2025	EX-99.2	Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that statements contained in this presentation regarding matters that are not Topline Phase 2 Results from Atumelnant in Congenital Adrenal Hyperplasia (CAH) January 10, 2025 Exhibit 99.
January 10, 2025	EX-99.1	Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% M Exhibit 99.1 Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione Meaningful Improvements Demonstrated in Multiple Clinical Signs and Symptoms of CAH Affecting Patient He
January 10, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (C
December 16, 2024	EX-99.1	Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer Exhibit 99.1 Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer SAN DIEGO – December 16, 2024 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company’s commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, o
December 16, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
December 9, 2024	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 09, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
December 9, 2024	EX-99.1	Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025 EXHIBIT 99.1 Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025 SAN DIEGO – December 9, 2024 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for investiga
November 14, 2024	SC 13G/A	CRNX / Crinetics Pharmaceuticals, Inc. / Point72 Asset Management, L.P. - CRINETICS PHARMACEUTICALS, INC. Passive Investment SC 13G/A 1 p24-3282sc13ga.htm CRINETICS PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 22663K107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of
November 14, 2024	SC 13G/A	CRNX / Crinetics Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 crnx13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 22663K107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check th
November 12, 2024	EX-99.1	Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of First Drug Candidate from a Novel Nonpeptide Drug Conjugate Platform at North American Neuroendocrine Tumor Society (NANETS) Total of Fo
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583
November 12, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
November 8, 2024	SC 13G	CRNX / Crinetics Pharmaceuticals, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 22663K107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria
November 8, 2024	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Crinetics Pharmaceuticals, Inc.
October 17, 2024	SC 13G/A	CRNX / Crinetics Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 CrineticsPharmaInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CRINETICS PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 22663K107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r
October 16, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (C
October 16, 2024	EX-10.2	Separation and Release Agreement, dated October 10, 2024, between Crinetics Pharmaceuticals, Inc. and James Hassard. Exhibit 10.2 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (this “Agreement”) is made and entered into by and between Crinetics Pharmaceuticals, Inc. (the “Company”) and James Hassard (“Employee”) (Employee and the Company collectively, the “Parties”). Whereas, Employee was employed by the Company as its Chief Commercial Officer; Whereas, the Company and Em
October 16, 2024	EX-10.1	Consulting Agreement, effective as of October 15, 2024, between Crinetics Pharmaceuticals, Inc. and James Hassard. Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into as of October 15, 2024 (the “Effective Date”) by and between Crinetics Pharmaceuticals, Inc. (the “Company”) and Jim Hassard (“Consultant”), an individual (each herein referred to individually as a “Party,” or collectively as the “Parties”). The Company desires to retain Consultant as an indepen
October 9, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Co
October 9, 2024	EX-99.2	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock Exhibit 99.2 Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock SAN DIEGO – October 8, 2024 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an upsized under
October 9, 2024	424B5	10,000,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-280407 Prospectus Supplement (To Prospectus dated June 21, 2024) 10,000,000 Shares Common Stock We are offering 10,000,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Select Market under the symbol “CRNX.” On October 8, 2024, the last reported sale price of our common stock on the Nasdaq Global S
October 9, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Crinetics Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables S-3 Crinetics Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number
October 9, 2024	EX-99.1	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock Exhibit 99.1 Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock SAN DIEGO – October 8, 2024 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subjec
October 9, 2024	EX-1.1	Underwriting Agreement, dated October 8, 2024, by and among Crinetics Pharmaceuticals, Inc. and Leerink Partners LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein EX-1.1 Exhibit 1.1 CRINETICS PHARMACEUTICALS, INC. 10,000,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement October 8, 2024 LEERINK PARTNERS LLC MORGAN STANLEY & CO. LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Leerink Partners LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Morgan Stanley & Co. LLC 1585 Broadway N
October 8, 2024	424B5	SUBJECT TO COMPLETION, DATED OCTOBER 8, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-280407 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
September 26, 2024	EX-99.1	Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly EXHIBIT 99.1 Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly SAN DIEGO – September 26, 2024 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agon
September 26, 2024	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation)
September 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation)
August 8, 2024	EX-99.1	Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Paltusotine NDA Submission in Acromegaly On Track for 2024 Topline Results from Phase 2 Studies of Atumelnant in Congenital Adrenal Hyperplasia and A EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Paltusotine NDA Submission in Acromegaly On Track for 2024 Topline Results from Phase 2 Studies of Atumelnant in Congenital Adrenal Hyperplasia and Additional Data for Phase 2 for ACTH-Dependent Cushing’s Syndrome Expected by End of 2024 Management Hosting Conference Call at 4:30 p.m.
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crine
August 8, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Co
June 24, 2024	424B5	Up to $350,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-280407 PROSPECTUS SUPPLEMENT (To Prospectus dated June 21, 2024) Up to $350,000,000 Common Stock On June 21, 2024, we entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”) and Cantor Fitzgerald & Co. (“Cantor”) relating to the offer and sale of shares of our common stock of
June 24, 2024	EX-FILING FEES	Calculation of Filing Fee Table (Form Type) Crinetics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forw Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) Crinetics Pharmaceuticals, Inc.
June 21, 2024	S-3ASR	As filed with the Securities and Exchange Commission on June 21, 2024 Table of Contents As filed with the Securities and Exchange Commission on June 21, 2024 Registration No.
June 21, 2024	EX-1.1	Sales Agreement, dated June 21, 2024, by and among Crinetics Pharmaceuticals, Inc., Leerink Partners LLC and Cantor Fitzgerald & Co. Exhibit 1.1 CRINETICS PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Sales Agreement June 21, 2024 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 Cantor Fitzgerald & Co. 110 E 59th Street New York, NY 10022 Ladies and Gentlemen: Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreemen
June 21, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Crinetics Pharmaceuticals, Inc.
June 21, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Comm
June 10, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Comm
June 3, 2024	EX-99.2	Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Dat Exhibit 99.2 Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine New PATHFNDR-1
June 3, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Commi
June 3, 2024	EX-99.3	Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that statements contained in this presentation regarding matters that are not Exhibit 99.3 Initial Phase 2 Results From Atumelnant* (CRN04894) in Congenital Adrenal Hyperplasia (CAH) and ACTH- dependent Cushing’s Syndrome (ADCS) June 3rd, 2024 * Proposed international nonproprietary name under review Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you tha
June 3, 2024	EX-99.1	Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS) 100% of Participants (n=6) With CAH Ma Exhibit 99.1 Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS) 100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg) CAH Participants Achieved More Tha
May 22, 2024	EX-99.1	Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts Exhibit 99.1 Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts SAN DIEGO – May 22, 2024 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that the late-breaking abstracts ac
May 22, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Commi
May 9, 2024	EX-10.1	Crinetics Pharmaceuticals, Inc. Excess Deferral Plan Adoption Agreement EXHIBIT 10.1 Crinetics Pharmaceuticals, Inc. Excess Deferral Plan Adoption Agreement Table of Contents 1.01 Preamble 1 1.02 Plan 1 1.03 Plan Sponsor 1 1.04 Employer 2 1.05 Administrator 2 1.06 Key Employee Determination Dates 2 2.01 Participation 3 3.01 Compensation 4 3.02 Bonuses 5 4.01 Participant Contributions 6 5.01 Employer Contributions 8 6.01 Distributions 11 7.01 Vesting 17 8.01 Unforeseea
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crin
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Commi
May 9, 2024	EX-99.1	Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cush EXHIBIT 99.1 Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing’s Syndrome Will be Presented at ENDO June 1-4, 2024 Following Second Positive Phase 3 Study (PATHFNDR-2), Paltusotine NDA Submission
May 8, 2024	EX-99.1	Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Finding EXHIBIT 99.1 Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial Data from Phase 3 PATHFNDR 1 and 2 Trials of Paltusotine in Acromegaly will be
May 8, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Commi
April 25, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
April 25, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
April 4, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Com
March 19, 2024	EX-99.1	Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients 56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Ge Exhibit 99.1 Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients 56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive Topline Results Support Planned NDA Submission to the FDA in 2H 2024 Manag
March 19, 2024	S-3ASR	As filed with the Securities and Exchange Commission on March 19, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 19, 2024 Registration No.
March 19, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Com
March 19, 2024	EX-99.2	Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that statements contained in this presentation regarding matters that are not Exhibit 99.2 Topline Results from Paltusotine Phase 3 PATHFNDR-2 Study A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety And Efficacy of Paltusotine in Subjects with Non- pharmacologically Treated Acromegaly March 19, 2024 1 Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,”
March 19, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Crinetics Pharmaceuticals, Inc.
March 12, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Com
March 12, 2024	EX-99.1	Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movement Exhibit 99.1 Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements Paltusotine was Generally Well-Tolerated and Showed an Overall PK Profile Consistent with Prior Studies Results Confirm Initial Positiv
March 12, 2024	EX-99.2	SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that statements contained in this presentation regarding matters that are not Results from Paltusotine Carcinoid Syndrome Open Label Phase 2 Study A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome Exhibit 99.
March 11, 2024	SC 13G	CRNX / Crinetics Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 22663K107 (CUSIP Number) February 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
March 1, 2024	EX-99.1	Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement Exhibit 99.1 FOR IMMEDIATE RELEASE Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement SAN DIEGO – February 28, 2024 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics” or the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related
March 1, 2024	EX-10.2	Registration Rights Agreement, dated February 27, 2024, by and among Crinetics Pharmaceuticals, Inc. and the persons party thereto. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 27, 2024, by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers set forth on Schedule 1 hereto (each, a “Purchaser”, and collectively, the “Purchasers”), and shall become effective as of the Closing (as defined in the Purchase Agr
March 1, 2024	SC 13D/A	CRNX / Crinetics Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d798461dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 22663K 107 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (6
March 1, 2024	EX-10.1	Securities Purchase Agreement, dated February 27, 2024, by and among Crinetics Pharmaceuticals, Inc. and the persons party thereto. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 27, 2024, by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Schedule 1 hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. On the terms and subject to
March 1, 2024	S-8 POS	As filed with the Securities and Exchange Commission on March 1, 2024 As filed with the Securities and Exchange Commission on March 1, 2024 Registration No.
March 1, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
February 29, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Crinetics Pharmaceuticals, Inc.
February 29, 2024	S-8	As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.
February 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc.
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
February 28, 2024	EX-99.1	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024 Pha EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024 Phase 2 Study of Paltusotine in Carcinoid Syndrome Full Topline Results Expected 1H 2024 Announced a $350 Million Private Placement Equity F
February 28, 2024	EX-19	Insider Trading Compliance Policy Exhibit 19 Crinetics Pharmaceuticals, Inc. Insider Trading Policy Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trade. Violating such laws can u
February 28, 2024	EX-10.14	First Amendment to Lease, dated December 8, 2023, to the Lease Agreement, dated as of September 9, 2022, by and between San Diego 1 LLC and the Registrant Exhibit 10.14 FIRST AMENDMENT TO LEASE (Crinetics Pharmaceuticals, Inc.) THIS FIRST AMENDMENT TO LEASE (this "First Amendment") is made and entered into as of December 8, 2023, by and between SAN DIEGO 1 LLC, a Delaware limited liability company ("Landlord") and CRINETICS PHARMACEUTICALS, INC., a Delaware corporation ("Tenant"; collectively with Landlord, the "Parties"; and each individually, a "P
February 28, 2024	EX-97	Clawback Policy Exhibit 97 CRINETICS PHARMACEUTICALS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION The Board of Directors (the “Board”) of Crinetics Pharmaceuticals, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined here
February 14, 2024	SC 13G/A	CRNX / Crinetics Pharmaceuticals, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga207422crnx02142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par
February 14, 2024	SC 13G/A	CRNX / Crinetics Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Passive Investment SC 13G/A 1 ss3005719sc13ga.htm AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 22663K107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this
February 14, 2024	SC 13G/A	CRNX / Crinetics Pharmaceuticals, Inc. / Point72 Asset Management, L.P. Passive Investment SC 13G/A 1 p24-0509sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 22663K107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp
February 14, 2024	EX-99.A	JOINT FILING AGREEMENT EX-99.A 2 ss3005719ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. 5 to the Statement on this Schedule 13G, dated December 31, 2023 (this “Schedule 13G”), with respect to the Common Stock, par value $0.001 per share, of Crinetics Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provi
February 14, 2024	SC 13G/A	CRNX / Crinetics Pharmaceuticals, Inc. / DRIEHAUS CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 schedule13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 2 )* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 22663K107 (CUSIP Number) December
February 14, 2024	SC 13G/A	CRNX / Crinetics Pharmaceuticals, Inc. / BRAIDWELL LP - SC 13G/A Passive Investment SC 13G/A 1 ef20021487sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CRINETICS PHARMACEUTICALS INC (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 22663K107 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statem
February 13, 2024	SC 13G	CRNX / Crinetics Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0704-crineticspharmaceutic.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Crinetics Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 22663K107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rul
February 8, 2024	SC 13G/A	CRNX / Crinetics Pharmaceuticals, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 22663K107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp
January 8, 2024	EX-99.1	Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” or “our”) cautions you that statements contained in this presentation regarding matters that are not histo Exhibit 99.1 nd 42 Annual J.P. MORGAN Healthcare Conference JA NUA RY 9 , 2 02 4 Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” or “our”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are base
January 8, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Co
December 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
December 18, 2023	EX-99.1	Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed P Exhibit 99.1 Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent with Prior Studies Phase 2 Study Enrollment is
December 18, 2023	EX-99.2	SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that statements contained in this presentation regarding matters that are not Initial Results from Ongoing paltusotine Carcinoid Syndrome Open Label Phase 2 Study A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome Exhibit 99.
December 12, 2023	EX-3.1	Amended and Restated Bylaws EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF CRINETICS PHARMACEUTICALS, INC. (a Delaware corporation) As Amended and Restated December 6, 2023 TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE. 1 1.2 OTHER OFFICES. 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS. 1 2.2 ANNUAL MEETING. 1 2.3 SPECIAL MEETING. 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUG
December 12, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2023 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
November 7, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Crinetics Pharmaceuticals, Inc.
November 7, 2023	EX-10.1	Amendment No. 3 to the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan Exhibit 10.1 AMENDMENT TO THE CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN THIS AMENDMENT TO the CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (this “Amendment”), effective as of November 5, 2023, is made and adopted by Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherwi
November 7, 2023	EX-99.1	Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-1 Study Met Primary and All Secondary Endpoints as Reported in September Phase 3 PATHFNDR-2 Study Topline Data Expected in 1Q 2024 I EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-1 Study Met Primary and All Secondary Endpoints as Reported in September Phase 3 PATHFNDR-2 Study Topline Data Expected in 1Q 2024 Initial Data from Phase 2 Study of Paltusotine in Carcinoid Syndrome Expected in December 2023 SAN DIEGO – November 7, 2023 – Crinetics Ph
November 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583
November 7, 2023	S-8	As filed with the Securities and Exchange Commission on November 7, 2023 As filed with the Securities and Exchange Commission on November 7, 2023 Registration No.
September 18, 2023	SC 13G	CRNX / Crinetics Pharmaceuticals Inc / Point72 Asset Management, L.P. - CRINETICS PHARMACEUTICALS, INC. Passive Investment SC 13G 1 p23-2430sc13g.htm CRINETICS PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 22663K107 (CUSIP Number) September 15, 2023 (Date of Event Which Requires Filing of this
September 18, 2023	EX-99.1	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additiona
September 13, 2023	424B5	Joint book-running managers J.P. Morgan Morgan Stanley Leerink Partners Piper Sandler Lead manager LifeSci Capital Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258694 Prospectus supplement (To prospectus dated August 10, 2021) 11,441,648 shares Common stock We are offering 11,441,648 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Select Market under the symbol “CRNX.” On September 12, 2023, the last reported sale price of our common stock
September 13, 2023	EX-1.1	Underwriting Agreement, dated September 12, 2023, by and among Crinetics Pharmaceuticals, Inc. and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Leerink Partners LLC and Piper Sandler & Co., as representatives of the several underwriters named therein Exhibit 1.1 CRINETICS PHARMACEUTICALS, INC. 11,441,648 Shares of Common Stock, par value $0.001 per share Underwriting Agreement September 12, 2023 J.P. MORGAN SECURITIES LLC MORGAN STANLEY & CO. LLC LEERINK PARTNERS LLC PIPER SANDLER & CO. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morga
September 13, 2023	EX-99.1	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock Exhibit 99.1 FOR IMMEDIATE RELEASE Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock SAN DIEGO – September 11, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it int
September 13, 2023	EX-99.2	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock Exhibit 99.2 FOR IMMEDIATE RELEASE Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock SAN DIEGO – September 12, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pr
September 13, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Crinetics Pharmaceuticals, Inc.
September 13, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Crinetics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry For Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Crinetics Pharmaceuticals, Inc.
September 11, 2023	EX-99.1	Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly 83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo ( EX-99.1 Exhibit 99.1 Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly 83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an Increase on Placebo (p<0.0001) After Switching from Injected De
September 11, 2023	424B5	Crinetics Pharmaceuticals, Inc. Attention: Corporate Secretary 10222 Barnes Canyon Road, Bldg. #2 San Diego, CA 92121 (858) 450-6464 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258694 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
September 11, 2023	EX-99.2	SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking EX-99.2 Exhibit 99.2 TOPLINE RESULTS FROM PALTUSOTINE PHASE 3 PATHFNDR-1 STUDY A Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics”) cautions yo
September 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2023 Crinetics Phar UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2023 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation)
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crine
August 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Co
August 8, 2023	EX-99.1	Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3 PATHFNDR-2 Study with Topline Data Expected in 1Q 2 EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3 PATHFNDR-2 Study with Topline Data Expected in 1Q 2024 Development of CRN04777 Suspended Company Hosting KOL Webinar on Acromegaly Treatment Landscape Today at 12:00 pm ET SAN DIEGO – Augu
June 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Comm
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crin
May 9, 2023	EX-10	Non-Employee Director Compensation Program, as amended effective as of April 24, 2023 Exhibit 10.2 CRINETICS PHARMACEUTICALS, Inc. Non-Employee DIRECTOR COMPENSATION PROGRAM As Amended Effective April 24, 2023 Non-employee members of the board of directors (the “Board”) of Crinetics Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the
May 4, 2023	EX-99	Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update EXHIBIT 99.1 Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update • Phase 3 PATHFNDR-1 study topline data expected in 3Q 2023 • Phase 3 PATHFNDR-2 study topline data expected in 1Q 2024 and enrollment target increased to up to 98 per prespecified protocol criteria • Paltusotine’s Phase 2 study in carcinoid syndrome on track for preliminary data in 4Q
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Commi
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
April 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
March 15, 2023	CORRESP	10222 Barnes Canyon Road, Bldg. 2, San Diego, California 92121 (858) 450-6464 www.crinetics.com 10222 Barnes Canyon Road, Bldg. 2, San Diego, California 92121 (858) 450-6464 www.crinetics.com March 15, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attn: Ibolya Ignat Angela Connell Re: Crinetics Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 30, 2022
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Com
February 28, 2023	EX-99	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023 - Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in 1Q 2024 - Pending a successful outcome from the PATHFNDR studies, an NDA submis
February 28, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc.
February 28, 2023	EX-10	Amendment No. 2 to the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan Exhibit 10.19 AMENDMENT TO THE CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN THIS AMENDMENT TO the CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (this “Amendment”), effective as of December 9, 2022, is made and adopted by Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherw
February 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
February 28, 2023	S-8	As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.
February 28, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Crinetics Pharmaceuticals, Inc.
February 14, 2023	EX-99.A	JOINT FILING AGREEMENT EX-99.A 2 ss1758566ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Common Stock, par value $0.001 per share, of Crinetics Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) und
February 14, 2023	SC 13G/A	CRNX / Crinetics Pharmaceuticals Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 22663K107 (CUSIP
February 14, 2023	SC 13G	CRNX / Crinetics Pharmaceuticals Inc / BRAIDWELL LP - SC 13G Passive Investment SC 13G 1 ny20007512x2sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CRINETICS PHARMACEUTICALS INC (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 22663K107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement)
February 14, 2023	SC 13G/A	CRNX / Crinetics Pharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Passive Investment SC 13G/A 1 ss1758566sc13ga.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. 4)* Under the Securities Exchange Act of 1934 Crinetics Pharmaceuticals Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 22663K107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this S
February 8, 2023	SC 13G/A	CRNX / Crinetics Pharmaceuticals Inc / DRIEHAUS CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1 )* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 22663K107 (CUSIP Number) December 31, 2022 (Date of Event Wh
February 6, 2023	SC 13G	CRNX / Crinetics Pharmaceuticals Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 22663K107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat
January 19, 2023	CORRESP	* * * * CORRESP 1 filename1.htm 10222 Barnes Canyon Road, Bldg. 2, San Diego, California 92121 (858) 450-6464 www.crinetics.com January 19, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attn: Ibolya Ignat Angela Connell Re: Crinetics Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31,
January 9, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (C
January 9, 2023	EX-99.1	SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking EX-99.1 2 crnx-ex991.htm EX-99.1 Developing GPCR-targeted oral small molecules for endocrine disorders and endocrine-related tumors Corporate presentation January 2023 Exhibit 99.1 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics”) cautions you that statements contained in this presentation regarding matters that are not histo
November 28, 2022	EX-99.1	Crinetics Pharmaceuticals Provides Update on CRN04777 Program EXHIBIT 99.1 Crinetics Pharmaceuticals Provides Update on CRN04777 Program SAN DIEGO, November 28, 2022 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI). On October 24, 2022, Crinetics submitted an
November 28, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
November 14, 2022	S-8	As filed with the Securities and Exchange Commission on November 14, 2022 As filed with the Securities and Exchange Commission on November 14, 2022 Registration No.
November 14, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Crinetics Pharmaceuticals, Inc.
November 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
November 14, 2022	EX-99.1	Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered and maintained IGF-1 at levels comparable to prior injected SRL therapy for up to 103 weeks in participants living with acromegaly participating in the ACROB
November 14, 2022	EX-10.3	Amendment to the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan Exhibit 10.3 AMENDMENT TO THE CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN THIS AMENDMENT TO the CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (this “Amendment”), effective as of September 9, 2022, is made and adopted by Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherw
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583
November 14, 2022	EX-10.1	Lease Agreement, dated as of September 9, 2022, by and between San Diego 1 LLC and the Registrant CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CRINETICS PHARMACEUTICALS, INC.
November 14, 2022	EX-10.2	Employment Agreement, effective as of September 30, 2022, by and between Dana Pizzuti and the Registrant Exhibit 10.2 Employment Agreement This Employment Agreement (the "Agreement") is made and entered into as of September 30, 2022, by and between Dana Pizzuti, MD (the "Executive") and Crinetics Pharmaceuticals, Inc, a Delaware corporation (the "Company"). WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth herein; and WHEREAS, the Executive desires to be emplo
October 13, 2022	EX-99.1	Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly Topline results for PATHFNDR-1 study expected in Q3 2023 EXHIBIT 99.1 Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly Topline results for PATHFNDR-1 study expected in Q3 2023 SAN DIEGO ? October 13, 2022 ? Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 stud
October 13, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (C
October 3, 2022	EX-99.1	Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer Exhibit 99.1 Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer SAN DIEGO, October 3, 2022 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer. Dr. Pizzuti is a board-certified physician with more than 30 years of pharmaceutical industry experience in clinical development, pharmacovigil
October 3, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 03, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (C
September 15, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation)
August 12, 2022	EX-99.1	Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Ph EXHIBIT 99.1 Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Paltusotine?s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing?s Disease and Congenital Adrenal Hyperplas
August 12, 2022	EX-FILING FEES	Calculation of Filing Fee Table (Form Type) Crinetics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forw Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) Crinetics Pharmaceuticals, Inc.
August 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Co
August 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number: 001-38583 Crine
August 12, 2022	424B5	Up to $150,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258694 PROSPECTUS SUPPLEMENT (To Prospectus dated August 10, 2021) Up to $150,000,000 Common Stock We previously entered into a Sales Agreement, or the Sales Agreement, with SVB Securities LLC, or SVB Securities, and Cantor Fitzgerald & Co., or Cantor, on August 13, 2019, relating to the offer and sale of shares of our common
June 21, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Comm
May 25, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Commi
May 25, 2022	EX-99.1	This presentation contains forward-looking statements. Crinetics cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s c CRN04894: Phase 1 Multiple ascending dose (MAD) Preliminary Results May 25, 2022 Exhibit 99.
May 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Commi
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number: 001-38583 Crin
May 12, 2022	EX-10.3	Consulting Agreement, dated as of April 1, 2022, by and between Ajay Madan and the Registrant Exhibit 10.3 CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) is made and entered into as of April 1, 2022 (the ?Effective Date?) by and between Crinetics Pharmaceuticals, Inc. (the ?Company?) and Ajay Madan (?Consultant?), an individual (each herein referred to individually as a ?Party,? or collectively as the ?Parties?). The Company desires to retain Consultant as an independent
May 12, 2022	EX-99.1	Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update EX-99.1 2 crnx-ex991.htm EX-99.1 Exhibit 99.1 Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update • Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 • Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated Top-Line Data Readouts in 2023 • Clinical Trial of CRN04777 in Congenital Hyperinsulinism Patients P
May 12, 2022	EX-10.2	License Agreement, dated as of February 25, 2022, by and between Sanwa Kagaku Kenkyusho Co., Ltd. and the Registrant CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CRINETICS PHARMACEUTICALS, INC.
April 28, 2022	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 28, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 26, 2022	SC 13D/A	CRNX / Crinetics Pharmaceuticals Inc / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 22663K 107 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address an
April 21, 2022	SC 13D/A	CRNX / Crinetics Pharmaceuticals Inc / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 22663K 107 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address an
April 13, 2022	EX-99.1	Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering Exhibit 99.1 FOR IMMEDIATE RELEASE Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering SAN DIEGO ? April 12, 2022 ? Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricin
April 13, 2022	424B5	5,625,563 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258694 PROSPECTUS SUPPLEMENT (To Prospectus dated August 10, 2021) 5,625,563 Shares Common Stock We are offering 5,625,563 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?CRNX.? On April 12, 2022, the last reported sale price of our common stock on th
April 13, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Crinetics Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry For Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Crinetics Pharmaceuticals, Inc.
April 13, 2022	EX-1.1	Underwriting Agreement, dated April 12, 2022, by and among Crinetics Pharmaceuticals, Inc., SVB Securities LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein Exhibit 1.1 CRINETICS PHARMACEUTICALS, INC. 5,625,563 Shares of Common Stock, par value $0.001 per share Underwriting Agreement April 12, 2022 SVB Securities LLC Evercore Group L.L.C. Cantor Fitzgerald & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o SVB Securities LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Evercore Group L.L.C. 55 East 52nd
April 13, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 Crinetics Pharmaceuticals, Inc.
March 31, 2022	S-8	As filed with the Securities and Exchange Commission on March 30, 2022 As filed with the Securities and Exchange Commission on March 30, 2022 Registration No.
March 31, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Crinetics Pharmaceuticals, Inc.
March 30, 2022	EX-99.1	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results – Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021 – – Advancing Phase 3 Exhibit 99.1 Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results ? Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021 ? ? Advancing Phase 3 PATHFNDR Program Evaluating Paltusotine in Acromegaly ? ? Advancing a Preclinical Parathyroid Hormone Receptor Antagonist Program Using t
March 30, 2022	EX-10.19	Employment Agreement, effective as of September 13, 2021, by and between Jeff Knight and the Registrant DocuSign Envelope ID: A7459A88-60C9-49A2-BDA6-A31093DE5357 Exhibit 10.19 Employment Agreement This Employment Agreement (the "Agreement") is made and entered into as of September 13, 2021, by and between Jeff Knight (the "Executive") and Crinetics Pharmaceuticals, Inc, a Delaware corporation (the "Company"). WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth
March 30, 2022	EX-10.17	Form of restricted stock unit agreement under Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan Exhibit 10.17 CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK Unit Grant Notice Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2021 Employment Inducement Incentive Award Plan (as amended from time to time, the ?Plan?) of Crinetics Pharmaceuticals, Inc.
March 30, 2022	EX-10.20	Employment Agreement, effective as of February 16, 2022, by and between James Hassard and the Registrant Exhibit 10.20 Employment Agreement This Employment Agreement (the "Agreement") is made and entered into as of February 16, 2022, by and between James Hassard (the "Executive") and Crinetics Pharmaceuticals, Inc, a Delaware corporation (the "Company"). WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth herein; and WHEREAS, the Executive desires to be employed
March 30, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38583 Crinetics Pharmaceuticals, Inc.
March 30, 2022	EX-10.18	Amended and Restated Employment Agreement, effective as of May 22, 2018, by and between Stephen Betz and the Registrant Exhibit 10.18 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into by and between Crinetics Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Stephen F. Betz (?Executive?), and shall be effective as of May 22, 2018 (the ?Effective Date?). WHEREAS, the Company and Executive previously entered into that certain E
March 30, 2022	EX-10.5	Form of restricted stock unit agreement under Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan Exhibit 10.5 CRINETICS PHARMACEUTICALS, INC. 2018 INCENTIVE AWARD PLAN RESTRICTED STOCK Unit Grant Notice Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the ?Plan?) of Crinetics Pharmaceuticals, Inc. (the ?Company?). The Company hereby grants t
March 30, 2022	EX-99.2	This presentation contains forward-looking statements. Crinetics cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s c CRN04777: Phase 1 Multiple ascending dose (MAD) preliminary Results March 30, 2022 Exhibit 99.
March 30, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Com
March 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Com
March 18, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Com
March 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (Com
March 14, 2022	EX-99.1	Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors Exhibit 99.1 Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors SAN DIEGO, March 14, 2022 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Caren Deardorf to the c
March 1, 2022	EX-99.1	Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer Exhibit 99.1 Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer SAN DIEGO, March 1, 2022 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the
March 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
February 28, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation) (
February 14, 2022	SC 13G/A	CRNX / Crinetics Pharmaceuticals Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 11, 2022	SC 13G/A	CRNX / Crinetics Pharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No.
February 11, 2022	SC 13G/A	CRNX / Crinetics Pharmaceuticals Inc / Vivo Capital VIII, LLC - AMENDMENT NO. 4 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 22663K107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the
February 11, 2022	EX-99.A	JOINT FILING AGREEMENT CUSIP No. 22663K107 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Common Stock, par value $0.001 per share, of Crinetics Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) unde
February 11, 2022	SC 13G/A	CRNX / Crinetics Pharmaceuticals Inc / Versant Venture Capital V, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3) Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 22663K 107 (C
February 10, 2022	SC 13G/A	CRNX / Crinetics Pharmaceuticals Inc / Struthers Richard Scott - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 22663K
January 12, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation or
January 10, 2022	SC 13G	CRNX / Crinetics Pharmaceuticals Inc / DRIEHAUS CAPITAL MANAGEMENT LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 22663K107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul
January 5, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation or O
January 5, 2022	EX-99.1	Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A. Exhibit 99.1 Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rog?rio Vivaldi Coelho, M.D., M.B.A. SAN DIEGO, January 5, 2022 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related t
December 23, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation or
December 23, 2021	EX-10.1	Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan and Form of Stock Option Agreement thereunder Exhibit 10.1 CRINETICS PHARMACEUTICALS, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. Purpose The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate Eligible Persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Ar
November 8, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation or
November 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number: 001-38583
November 5, 2021	EX-99.1	Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update – Pipeline Includes Three New Chemical Entities with Clinical Proof-of-concept Following CRN04894 and CRN04777 Phase 1 Readouts – – Advancing a Parat Exhibit 99.1 Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update ? Pipeline Includes Three New Chemical Entities with Clinical Proof-of-concept Following CRN04894 and CRN04777 Phase 1 Readouts ? ? Advancing a Parathyroid Hormone Receptor Antagonist Program Using the Drug Development Blueprint Followed by Paltusotine, CRN04894, and CRN04777 ? ? Co-fo
November 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2021 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation or
October 29, 2021	SC 13G	CRNX / Crinetics Pharmaceuticals Inc / BIOTECHNOLOGY VALUE FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Crinetics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 22663K 10 7 (CUSIP
October 29, 2021	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated October 29, 2021 with respect to the shares of Common Stock, par value $0.001 per share of Crinetics Pharmaceuticals, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and
October 21, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2021 Crinetics Pharmaceuticals, Inc.
October 21, 2021	EX-99.2	Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock Exhibit 99.2 FOR IMMEDIATE RELEASE Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock SAN DIEGO ? October 21, 2021 ? Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing
October 21, 2021	424B5	CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED AMOUNT TO BE REGISTERED PROPOSED MAXIMUM OFFERING PRICE PER SHARE PROPOSED MAXIMUM AGGREGATE OFFERING PRICE AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.001 par valu Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258694 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED AMOUNT TO BE REGISTERED PROPOSED MAXIMUM OFFERING PRICE PER SHARE PROPOSED MAXIMUM AGGREGATE OFFERING PRICE AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.001 par value per share 8,712,400(1) $19.80 $172,505,520 $15,992 (1) Includes share
October 21, 2021	EX-1.1	Underwriting Agreement, dated October 20, 2021, by and among Crinetics Pharmaceuticals, Inc. and SVB Leerink LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein Exhibit 1.1 Execution Version CRINETICS PHARMACEUTICALS, INC. 7,576,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement October 20, 2021 SVB Leerink LLC Evercore Group L.L.C. Cantor Fitzgerald & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o SVB Leerink LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Evercore Group L.L.C
October 21, 2021	EX-99.1	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock Exhibit 99.1 FOR IMMEDIATE RELEASE Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock SAN DIEGO ? October 20, 2021 ? Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it inten
October 20, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2021 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation or
October 20, 2021	424B5	SUBJECT TO COMPLETION, DATED OCTOBER 20, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258694 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these
October 18, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation or
September 27, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation o
September 15, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 Crinetics Phar UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation o
September 15, 2021	EX-99.1	Phase 1 Pharmacologic Proof-of-Concept for CRN04777 in Healthy Volunteers CRINETICS PHARMACEUTICALS \| 3 CRN04777: First in Human single ascending dose (SAD) Preliminary Results September 15, 2021 Exhibit 99.
September 2, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2021 Crinetics Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38583 26-3744114 (State or Other Jurisdiction of Incorporation or O

CRNX / Crinetics Pharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings